SCHEMBL24409273

SCHEMBL24409273

Cc1nn(-c2ccc(C=O)cn2)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 1/20 0.49
GCG P01275 1/20 0.38
KDM4E B2RXH2 1/20 0.36
DYRK3 O43781 1/20 0.33
CCNT1 O60563 1/20 0.33
CDK9 P50750 1/20 0.33
CDK5 Q00535 1/20 0.33
DYRK1A Q13627 1/20 0.33
CDK5R1 Q15078 1/20 0.33
DYRK2 Q92630 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
BRD4 O60885 1/20 0.32
CYP2A6 P11509 1/20 0.32
HSD17B10 Q99714 1/20 0.32
EGLN1 Q9GZT9 2/20 0.31
ALDH3A1 P30838 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30630814 1.00 KCNJ1 (0.49) KCNJ1GCGKDM4EDYRK3CCNT1
SCHEMBL30630891 0.85 KCNJ1 (0.51) KCNJ1KDM4EALDH1A1MEN1KMT2A
SCHEMBL24409437 0.82 KCNJ1 (0.49) KCNJ1KDM4EALDH1A1BRD4CYP2A6
SCHEMBL11901321 0.77 KDM4E (0.36) GCGKDM4EMEN1KMT2AEGLN1
SCHEMBL19121333 0.77 GCG (0.38) GCG
SCHEMBL29972961 0.74 KCNJ1 (0.53) KCNJ1KDM4EALDH1A1HSD17B10EGLN1
SCHEMBL30444808 0.74 KCNJ1 (0.56) KCNJ1KDM4EALDH1A1MEN1MAPT
SCHEMBL24409429 0.74 KCNJ1 (0.53) KCNJ1KDM4EALDH1A1MEN1MAPT
SCHEMBL20168052 0.74 KCNJ1 (0.56) KCNJ1KDM4EALDH1A1MEN1MAPT
SCHEMBL20168186 0.73 KCNJ1 (0.46) KCNJ1KDM4EALDH1A1EGLN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220144847-A1 HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF ELLIPSES PHARMA LTD (GB) 2022-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144847-A1 HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF NOTUM, FURIN, CYP4A11 KCNJ1 2287/4885GCG 595/4885KDM4E 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.